Decreased plasma endothelin-1 levels in children with sickle cell disease treated with hydroxyurea.
Plasma endothelin-1 (ET-1) is elevated in patients with sickle cell disease (SCD). Hydroxyurea (HU) is the only drug with demonstrated clinical efficacy in SCD. Here we show that treatment with HU results in a decreased concentration of circulating ET-1 which is not correlated with the HU-induced increase in HbF level. Blunting of the ET-1 vasoconstrictive stimulus could contribute to the beneficial effects of HU.
Lapouméroulie
Claudine
C
Benkerrou
Malika
M
Odièvre
Marie Hélène
MH
Ducrocq
Rolande
R
Brun
Manuel
M
Elion
Jacques
J
D000755:Anemia, Sickle Cell / Q000097:blood / Q000188:drug therapy*; D016022:Case-Control Studies; D002648:Child; D019332:Endothelin-1 / Q000097:blood*; D005319:Fetal Hemoglobin / Q000032:analysis; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*
D019332:Endothelin-1; D005319:Fetal Hemoglobin; D006918:Hydroxyurea